We are live on ! Find out more

Axsome Therapeutics

AXSM

Market cap $11.6B

220.75 USD

+9.63

4.56%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

220.75

0.00

0%

1 day

4.56%

5 days

6.64%

1 month

2.31%

3 months

-13.01%

6 months

38.4%

Year to date

23.54%

1 year

79.53%

5 years

703.31%

10 years

2,875.07%

About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Employees: 925

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27%

Neutral 51.4%

Negative 21.6%

The Motley Fool

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Axsome Therapeutics is scaling revenue rapidly through its portfolio of central nervous system treatments. CRISPR Therapeutics is pioneering the commercial stage of gene-editing technology with its first approved therapy.

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

The Motley Fool

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Axsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue from its central nervous system treatments. Viking Therapeutics remains a clinical-stage player with significant potential in the high-demand obesity and metabolic disease markets.

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Zacks Investment Research

Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m.

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Zacks Investment Research

Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.

Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults.

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

The Motley Fool

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion in free cash flow for fiscal 2025.

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run

Axsome Therapeutics is performing well as it continues to expand its approved portfolio. The company's deep pipeline may help it launch newer products and post consistent revenue growth for a while.

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run

See News Rankings

Price charts implemented using Lightweight Charts™